SCHEMBL12238017

SCHEMBL12238017

CCOC(=O)COc1ccc2c(=O)c(-c3ccccn3)coc2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.74
GAA P10253 1/20 0.74
MEN1 O00255 6/20 0.71
KMT2A Q03164 6/20 0.71
POLB P06746 2/20 0.71
ALDH2 P05091 6/20 0.67
ALDH1A1 P00352 5/20 0.59
KDM4E B2RXH2 3/20 0.55
HPGD P15428 1/20 0.55
MAOA P21397 2/20 0.52
MAOB P27338 2/20 0.52
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.49
ADORA2A P29274 1/20 0.46
TP53 P04637 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8983972 0.85 MAPT (1.00) MAPTGAAMEN1KMT2APOLB
SCHEMBL2107428 0.83 ALDH2 (0.90) MAPTGAAMEN1KMT2APOLB
SCHEMBL10624579 0.81 ALDH2 (0.86) MAPTGAAMEN1KMT2APOLB
SCHEMBL12238006 0.81 MAPT (0.69) MAPTGAAMEN1KMT2APOLB
SCHEMBL13856172 0.81 RAB9A (0.67) MAPTGAAMEN1KMT2APOLB
SCHEMBL10624708 0.81 ALDH2 (1.00) MAPTGAAMEN1KMT2APOLB
SCHEMBL10620446 0.80 ALDH2 (0.83) MAPTGAAMEN1KMT2APOLB
SCHEMBL11551965 0.77 MEN1 (0.75) MAPTGAAMEN1KMT2APOLB
SCHEMBL11013715 0.76 MAPT (0.81) MAPTGAAMEN1KMT2APOLB
SCHEMBL11011560 0.75 ALDH2 (0.67) MAPTGAAMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9408826-B2 Isoflavone anti-viral compounds Kineta, Inc. (US) 2016-08-09 US disclosed
US-9408826-B2 Isoflavone anti-viral compounds Kineta, Inc. (US) 2016-08-09 US disclosed
US-20110262482-A1 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 US disclosed
US-20110262482-A1 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110262482-A1 ANTI-VIRAL COMPOUNDS MAVS, EIF2AK2, IRF3 MAPT 3520/4885GAA 1456/4885MEN1 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.